![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom
The hepatic uptake of imipramine and propranolol was investigated after incubation with isolated rat hepatocytes over a wide concentration range (0.04400 µM). The cell-to-medium concentration ratio (Kp) was concentration-dependent and could be described using a two-site binding model incorporating a high affinity/low capacity site and a linear component for a site which was apparently not saturated. Maximum (at 0.04 µM) and minimum Kp values (at 400 µM) were 360 and 280, and 110 and 70 for imipramine and propranolol, respectively. During these incubations, metabolism was inhibited using aminobenzotriazole (an irreversible inhibitor of cytochrome P450). Pretreatment of cells either by freeze-thawing or with saponin (which permeabilizes the plasma membrane) eliminated the saturable process. The saturable uptake process of imipramine was also inhibited by 18 other lipophilic amine drugs (including propranolol). This uptake component may involve membrane transporter(s), whereas the nonsaturable component probably represents partition into the phospholipid component of membranes. Propranolol was further investigated to determine the impact of high Kp values on hepatocellular clearance. The area under the curve for propranolol concentrations in the total incubate (medium including the cells) from the depletiontime profile was substantially greater than the corresponding area under the curve for the drug concentration in the extracellular medium, and this difference approximated the nonsaturable uptake component. It is concluded that the clearance of propranolol in isolated hepatocytes is not rate-limited by hepatic uptake and is directly proportional to unbound drug concentration, being independent of the higher Kp value.
This article has been cited by other articles:
![]() |
A. Poirier, T. Lave, R. Portmann, M.-E. Brun, F. Senner, M. Kansy, H.-P. Grimm, and C. Funk Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model Drug Metab. Dispos., December 1, 2008; 36(12): 2434 - 2444. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Paine, A. J. Parker, P. Gardiner, P. J. H. Webborn, and R. J. Riley Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes Drug Metab. Dispos., July 1, 2008; 36(7): 1365 - 1374. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rowland, D. J. Elliot, K. M. Knights, P. I. Mackenzie, and J. O. Miners The "Albumin Effect" and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9 Drug Metab. Dispos., May 1, 2008; 36(5): 870 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hallifax and J. B. Houston Saturable Uptake of Lipophilic Amine Drugs into Isolated Hepatocytes: Mechanisms and Consequences for Quantitative Clearance Prediction Drug Metab. Dispos., August 1, 2007; 35(8): 1325 - 1332. [Abstract] [Full Text] [PDF] |
||||